Cannula Market Size & Outlook, 2026-2034

Cannula Market Overview

The global cannula market size was estimated at USD 204.22 million in 2025 and is anticipated to grow from USD 218.69 million in 2026 till USD 388.52 million in 2034, growing at a CAGR of 7.45% from 2026 to 2034. Growth is fueled by the increasing incidence of chronic diseases, coupled with more hospital and outpatient procedures, and the accelerated adoption of minimally invasive surgeries.

Key Market Trends & Insights

• North America held a dominant share of the global market, accounting for 41.02% share in 2025, driven by high surgical volumes, chronic disease-related infusion therapies, adoption of safety cannulas under strict regulations, and the strong presence of leading manufacturers.
• The Asia Pacific region is growing at the fastest pace, with a CAGR of 8.92%, due to several factors, such as the presence of a large geriatric population and supportive government initiatives that improve accessibility to high-quality cannulas.
• Based on the Product Type, the intravenous cannula segment held the highest market share of 36.53% in 2025, attributed to various reasons, such as it is wide use in hospitals and other healthcare settings for medicine administration and fluid therapy.
• Based on the Application, the oxygen delivery segment is expected to register the fastest CAGR growth of 8.21%. The growth is attributed to the increasing prevalence of respiratory diseases and rising demand for home-based oxygen therapy.
• Based on Sizes, the 18G segment dominated the market in 2025. The growth is attributed to its broad applicability, adaptability, and capacity to satisfy the requirements of numerous medical operations.
• Based on Material, the plastic segment dominated the market in 2025. The growth is attributed to cost-effectiveness, disposability, and lightweight design, making it widely preferred in hospitals, clinics, and home healthcare settings.
• Based on End User, the hospitals and clinics segment dominated the market in 2025 with a revenue share of 55%. The growth is attributed to increasing patient inflow, availability of advanced healthcare infrastructure, and preference for professional administration of IV therapies.
• The U.S. dominates the global cannula market, valued at USD 76.81 million in 2024 and reaching USD 82.20 million in 2025.

Market Size and Forecast

• 2025 Market Size: USD 204.22 million
• 2034 Projected Market Size: USD 388.52 million
• CAGR (2025 to 2034): 7.45%
• Dominating Region: North America
• Fastest-Growing Region: Asia Pacific

Source: Straits Research Analysis

Cannulas are integral in intravenous therapies, fluid management, and drug administration, making them essential in both routine and critical care.

In addition, the growing demand for home healthcare solutions has boosted the use of cannulas for long-term therapies, particularly in elderly and chronic care patients. Continuous product innovations, including safety-engineered cannulas that reduce the risk of needlestick injuries and smart cannulas with integrated monitoring features, are further enhancing procedural efficiency and patient outcomes.

With hospitals, clinics, and home care providers emphasizing patient safety, infection prevention, and workflow optimization, manufacturers are increasingly focusing on developing multi-functional, portable, and user-friendly cannulation devices. These factors collectively position the global cannula market for sustained expansion over the coming years.

Market Trends

Shift from Standard to Safety-Engineered Cannulas

Manufacturers are transitioning from the standard cannulas to safety-engineered products that reduce the needlestick injuries and blood exposure, which further drives the market growth.

• For example, in March 2024, B. Braun launched the Introcan Safety 2 IV Cannula, and similarly in September 2023, Rocialle Healthcare launched Safnule, a closed system IV cannula with needle-free connectors.

Such innovation drives the growth by enabling manufacturers to command premium pricing, as well as strengthening brand reputation, which thereby expands their presence in the cannula sector.

Cannula Adoption in Robotic-Assisted Surgery

Cannula applications are moving from conventional manual procedures to integration with robotic-assisted platforms as it improves precision, flexibility and also minimizes tissue damage during the surgeries.

• For example, in January 2025, as per the data reported in Springer Nature, researchers at the University of Nevada, Las Vegas, developed a single-port, dual-arm robotically steerable endoscope with a major as well as two minor cannulas for precise neurosurgical tasks.

Such innovations boost the demand for specialized cannulas in robotic-assisted surgeries, which further fuels the market growth.

To get more insights about this report Download Free Sample Report

Market Drivers

Growing Adoption of Cannulas in Home Healthcare

Rising adoption of cannulas for home healthcare drives the market growth as patients, especially the elderly, increasingly seek safe, portable, as easy-to-use cannulas for at-home intravenous therapy. Such a factor encourages manufacturers to develop home care-friendly, safe and easy-to-use products, which boosts overall growth.

Government Initiatives Are Accelerating the Expansion of Cannula Production

Supportive government policies are focusing towards improving access to raw materials, which further fuels the growth of cannula sector.

• For instance, in June 2025, the Indian government exempted the imported medical-grade plastic from mandatory BIS certification, which allows manufacturers to secure high-quality materials more easily.

Such factor reduces production delays, lowers costs, and ensures consistent manufacturing across various gauge sizes, which collectively drives the overall market growth.

Market Restraint

High Failure Rates and Procedural Challenges

The cannulation market faces significant procedural challenges, that restrain the market growth as it includes high failure rates and repeated insertion attempts.

• For example, in June 2025, as per the data reported in Salisbury Robotics Lab, nearly 250 million IV cannulation takes place in U.S. annually, yet 28% and 54% of the insertions fail on the first attempt in adults as well as children respectively.

This challenge not only hampers cannula adoption but also drives the use of substitute products, thus hampering the sector’s growth.

Market Opportunity

Expansion of Domestic Manufacturing Capacity for Iv Cannulas

A key opportunity in the cannula market is the expansion of local manufacturing to meet the growing demand for IV cannulas.

• For example, in January 2025, BD (Becton, Dickinson and Company) announced plans to invest over USD 30 million to expand manufacturing capacity for intravenous (IV) lines at its Utah facility. This strategic move builds on a previous USD 2 million investment in 2024, which increased annual IV cannula output by 40 million units.

Such factor strengthens the domestic production capabilities by focusing on the rising demand for IV cannula, hence expanding the market growth.

Regional Analysis

The North America region dominated the market with a revenue share of 41.02% in 2025. The growth is attributed to factors such as high surgical volumes, chronic disease-related infusion therapies, adoption of safety cannulas under strict regulations, and the strong presence of leading manufacturers.

Asia Pacific Market Growth Factors

The Asia Pacific region is the fastest-growing region with a CAGR of 8.92% during the forecast timeframe. The growth is attributed to factors such as a rapidly expanding population base, government initiatives to strengthen the healthcare infrastructure as well as the presence of domestic manufacturing hubs that support the wider accessibility of cannulas.

Source: Straits Research Analysis

Countries Analysis

• U.S.: The cannula market in U.S. is widely driven by the increasing adoption of minimally invasive procedures, particularly in neurosurgery. For example, in May 2024, the FDA authorized the SmartFlow Neuro Cannula by ClearPoint Neuro, Inc. This device is the first FDA-authorized cannula designed for precise drug delivery within the brain.
• UK: The cannula market in UK is propelling due to rising government investments in medical technology as well as a growing emphasis on cost-effective and sustained healthcare solutions, which further enhances the market growth.
• Germany: In Germany, the cannula industry is driven by the rising prevalence of chronic diseases and adoption of safety-engineered cannulas in the country. For example, in 2025, B. Braun Melsungen AG launched the Introcan Safety 2 IV cannula in Germany with an aim of enhancing patient safety.
• China: The cannula market in China is fuelled by the country's booming healthcare market, mostly driven by increase in aging population, a rise in chronic diseases and also the increased demand for minimally invasive procedures, such as cosmetic treatments that would require cannulisation.
• India: India continues to position itself in the market for cannula, due to its rapidly growing population, and rising incidence of non-communicable diseases, such as diabetes and cardiovascular disorders, is increasing the demand for intravenous therapies, which further drives the market growth.

Product Insights

The intravenous cannula segment dominated the market with a revenue share of 36.53% in 2025. The growth is attributed to rapid as well as efficient routes of administering fluids into the bloodstream, and its frequent use in chemotherapy, dialysis as well as both pre and post-surgical care.

Source: Straits Research Analysis

Application Insights

The oxygen delivery segment is anticipated to grow at a CAGR of 8.21% during 2026 - 2034. This growth is attributed to the rising prevalence of chronic respiratory diseases, such as COPD as well as asthma, age-related breathing difficulties, and the growing demand for supplemental oxygen therapy in both hospital as well as home care settings.

Sizes Insights

The 18G segment dominated the market in 2025. This growth is attributed to the wide preference of 18G sizes in hospitals for the balance between the flow rate and patient comfort. In addition, they are commonly used for administering IV fluids, blood transfusions and medications in both emergency as well as routine care.

Material Insights

The plastic segment dominated the market in 2025. The growth is attributed to ease of manufacturing across multiple gauges, compatibility with advanced IV systems, flexibility for patient comfort, and the ability to integrate with safety-engineered features.

End-User Insights

The hospitals and clinics segment dominated the market in 2025 with a revenue share of 55%. This growth is attributed to the hospitals handling the largest volume of patients that require intravenous therapy, surgeries, oxygen delivery as well as blood transfusions, in which most of them rely on the cannulas.

Competitive Landscape

The global cannula market is highly fragmented in nature due to the presence of numerous international, regional as well as local players offering diverse product portfolios at competitive pricing. The top players are Medtronic, BD, Edwards Lifesciences Corporation, LivaNova PLC, United Medical Supply and Others.

The industry participants are inclined towards adopting key business strategies, such as strategic collaborations, product approvals, acquisitions, and product launches, to gain a strong foothold in the market.

Clearpoint Neuro, Inc.: An Emerging Market Player

ClearPoint Neuro, Inc. is a device, cell as well as gene therapy enabling company that offers precise navigation to the brain as well as spine.

• In November 2024, ClearPoint Neuro, Inc. received FDA approval for the SmartFlow Neuro Cannula using the De Novo pathway for delivering gene therapy directly to the regions of interest within the brain.

List of key players in Cannula Market

1. Medtronic
2. BD
3. Edwards Lifesciences Corporation
4. LivaNova PLC
5. United Medical Supply
6. Boston Scientific Corporation
7. ICU Medical, Inc
8. Braun
9. Deltamed
10. Medikit Europe GmbH
11. Terumo Cardiovascular Systems Corporation
12. NIPRO
13. Vitality Medical, Inc
14. Cardinal Health
15. ANGIPLAST PRIVATE LIMITED
16. AdvaCare Pharma
17. Narang Medical Limited
18. Romsons
19. CONMED Corporation
20. Fisher & Paykel Healthcare Limited

To get more findings about this report Download Market Share

Recent Development

• September 2024: Braun Medical Inc. received FDA clearance for the Introcan Safety 2 Deep Access IV Catheter, which is the newest addition to the Introcan Safety 2 IV Catheter portfolio.
• August 2025: In August 2025, the U.S. FDA issued an Early Alert regarding certain cardiac cannula products from Medtronic. Several lots were found to resist shape retention when bent, meaning the cannula shaft failed to maintain its intended bend during use. This defect posed risks such as procedural delays, abrasion, or vascular perforation if unnoticed. While three serious injuries were reported, no fatalities occurred. Medtronic has since addressed the issue in newer production lots, though short-term supply limitations may impact availability. This incident underscores the critical importance of quality control and regulatory vigilance in high-risk cardiovascular devices.
• July 2025: RAUMEDIC AG developed and patented a single-piece, injection-molded soft cannula, which is safer, more efficient as well as cost-effective.
• July 2025: In mid-2025, Edwards Lifesciences initiated a recall of its OptiSite Arterial Perfusion Cannula and certain Femoral Arterial Cannula models, including the FEM-Flex II. The FDA classified the action as a Class I recall its most serious designation, due to a defect in which the wire reinforcement coil near the cannula tip could protrude 3–4 mm. This raised the risk of bleeding, tissue damage, or vessel perforation during use. The recall highlights both the safety-critical role of cannulae in cardiopulmonary procedures and the ongoing regulatory oversight shaping this market.

Analyst Opinion

The global cannula market is fueling due to the rising demand for minimally invasive procedures, driving adoption in surgical, cardiovascular as well as aesthetic applications. The increasing prevalence of chronic diseases requires intravenous therapy and critical care, which further fuels the market demand. Moreover, supportive regulatory approvals as well as expansion of healthcare infrastructure across the emerging economies are facilitating wider product penetration, which further expands the market growth. Collectively, all these factors combined boost the adoption, improve the treatment outcomes and also strengthen the global medical device ecosystem for the cannula applications.